ArticleMedicine2026
Knowledge mapping of targeted therapy for hypertrophic cardiomyopathy: A bibliometric analysis of myosin inhibitor research.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTargeted therapy using myosin inhibitors represents a groundbreaking advancement in the management of hypertrophic cardiomyopathy (HCM). This study conducts a comprehensive bibliometric analysis to map the research landscape indexed in the Web of Science Core Collection, identify key trends, and evaluate the scientific impact of myosin inhibitor studies from 2016 to 2025.
methodsWe systematically retrieved publications from the Web of Science Core Collection using predefined search terms related to myosin inhibitors and HCM. Utilizing VOSviewer software, CiteSpace, and R-Bibliometrix Package, we performed co-authorship, co-citation, and keyword co-occurrence analyses. Bibliometric indicators (e.g., publication volume, citations, h-index) were employed to assess research productivity and influence.
resultsThis bibliometric analysis encompassed 379 publications (2016-2025) on myosin inhibitors for HCM, showing exponential growth. The United States dominated research output (37% of total publications), followed by Italy (30 publications) and Germany (14 publications). Leading institutions included the University of Pennsylvania (39 publications, 1585 citations) and Bristol Myers Squibb (32 publications). Journal of the American College of Cardiology emerged as the top publishing venue (16 papers, 937 citations). Key researchers were identified: Olivotto I (most productive, 40 papers, h-index = 16), Saberi S (most cited, 1957 citations), and Sehnert AJ (highest impact, h-index = 16 with 27 papers). Three research phases were evident: mechanistic (2016-2018), clinical translation (2019-2021), and personalized therapy (2022-2025), with AI applications showing 4.2% annual growth. Citation networks showed that foundational studies (e.g., Green et al, 2016) were frequently cited by subsequent clinical research, reflecting a temporal citation pattern in which earlier mechanistic publications were frequently referenced by later clinically focused studies.
conclusionsThis study presents a descriptive bibliometric overview of publication patterns for myosin inhibitor research in HCM, describing the publication patterns and collaborative networks that characterize this field. While North America and Europe lead productivity, global collaboration gaps persist. Future research should prioritize real-world evidence, combination therapies, and equitable knowledge dissemination. These findings offer strategic insights for researchers, funders, and policymakers advancing targeted HCM therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.